The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ, LCMC2 investigators
Clin Cancer Res. 2018 24 (5): 1038-1047

PMID: 29217530 · PMCID: PMC7008001 · DOI:10.1158/1078-0432.CCR-17-2289

MeSH Terms (23)

Adenocarcinoma of Lung Adult Aged Aged, 80 and over Antineoplastic Agents Biomarkers, Tumor Carcinogenesis DNA Mutational Analysis Female High-Throughput Nucleotide Sequencing Humans Lung Neoplasms Male Middle Aged Molecular Targeted Therapy Mutation Prognosis Prospective Studies Smoking Survival Analysis Treatment Outcome Tumor Suppressor Protein p53 Young Adult

Connections (1)

This publication is referenced by other Labnodes entities:

Links